RA Capital Management’s Post

It is all about giving back to the community. Do you know that scientists like to invest in other scientists? Because they understand each other. They also see through those who don't have anything of substance. After the recent acquisition of RayzeBio, co-founder Aaron Kantoff turned around and is putting the capital back into the science community that made this opportunity bloom. Are you investing back? #vcfunding #biotechinnovation #sandiego https://lnkd.in/gyjrAuW4

Today marks a pivotal moment in the journey of Caixa Capital Risc as we are unveiling our latest endeavor: Say hello to our two new evergreen funds - Criteria Venture Tech and Criteria Bio Ventures! 🌟 These funds are a testament to our innovative spirit and our commitment to forward-thinking innovation in the realms of tech and biotech. 🌐 By following us, you'll stay updated on cutting-edge developments and breakthroughs in these dynamic sectors. Our goal is to keep you informed about the latest news, investment thesis, remarkable portfolio milestones, and the ins and outs of our VC. 📈 💼 #CriteriaVentureTech #CriteriaBioVentures #investment #innovation #tech #Biotech #LifeScience

👋 Bye-bye, generalist investors! 👋 Specialized biotech VC firms are taking the reins! 🚀 The biotech industry is on the move, and specialized biotech VC firms are leading the way! 💯 These experts understand the complexities of the sector, from scientific nuances to regulatory hurdles. 🧠🏛️ No more generalist investors diving in unawares! ⚠️ Specialized VCs are here to stay, and they're making waves in groundbreaking biotech! 🌊🧪 #biotech #venturecapital #specializedvcinvestors #generalistinvestors #covid19 #healthcare #innovation

Like science founders know all too well that running a lean organization and keeping costs down are vital for hitting milestones and attracting additional capital (especially in today's challenging funding climate). Join us for a three-part series to SPEED UP & DE-RISK your venture: April 4, April 18, May 2 Extend cash runway and maximize potential with a virtual biotech model. Register now and join the conversation! https://lnkd.in/g__qagsV #StartupLife #VirtualBiotech #RegisterToday

🚀 Belgian biotech: a beacon for VCs in uncertain times 🚀 🔬 Amid a global funding dip, with Belgian growth companies raising €770 million in 2023, half of 2022's record, biotech stands strong. VIB spin-offs Aphea.Bio and Dualyx are leading the charge with notable capital increases. Congratulations to their respective teams! 💡 These successes are not just outliers but a testament to VIB's excellence in cultivating top-tier biotech spin-offs. In a landscape marked by economic headwinds, VIB spin-offs are able to navigate heavy seas. 🌟 For venture capitalists seeking resilient and promising investments, VIB's track record is a beacon. Keep an eye out for some of our promising pipeline opportunities in 2024! #biotech #lifesciences #earlystage #venturecapital #innovation #VIB #Belgium #strategicinvestment Source: https://lnkd.in/e-PXcVqs

A conversation about a topic that lies at the heart of ClavystBio - translating great science into new companies and ultimately medicines. Watch it here!

Want to find out what our new 65LAB collaboration has in common with Guardians of the Galaxy? Check out our partner ClavystBio's latest Conversations episode for the answer.... #researchneverstops

Want to find out what our new 65LAB collaboration has in common with Guardians of the Galaxy? Check out our partner ClavystBio's latest Conversations episode for the answer.... #researchneverstops

Three experts provide valuable insights into how founders can deal with an apparent paradox: building a competent team for the demanding tasks of a biotech start-up, while at the same time financing the company is becoming increasingly difficult. Many thanks to Helena Strigård for the succinct statements. https://lnkd.in/dzXGuzBz #biotech #constares #HaegerCarlsson

Fierce Biotech has published an insightful article on the EU biotech industry. In the article, Forbion Managing Partner Sander Slootweg shares his perspective on the industry's performance in 2023 and what we can expect in 2024. Check it out to stay up-to-date on the latest developments in biotech! #BiotechIndustry #Forbion #FierceBiotech #leaders #insight #biotech #lifesciences